RevitaCAM

Country: European Union

Language: English

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

meloxicam

Available from:

Zoetis Belgium SA

ATC code:

QM01AC06

INN (International Name):

meloxicam

Therapeutic group:

Dogs

Therapeutic area:

Oxicams

Therapeutic indications:

Alleviation of inflammation and pain in both acute and chronic musculoskeletal disorders in dogs.

Product summary:

Revision: 5

Authorization status:

Withdrawn

Authorization date:

2012-02-23

Patient Information leaflet

                                Medicinal product no longer authorised
1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
Medicinal product no longer authorised
2
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
RevitaCAM 5 mg/ml oromucosal spray for Dogs
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each ml contains:
ACTIVE SUBSTANCE: Meloxicam 5 mg
EXCIPIENTS: Ethyl alcohol 150 mg
For a full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Oromucosal spray
Yellow colloidal dispersion
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Dogs
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
Alleviation of inflammation and pain in both acute and chronic
musculo-skeletal disorders in dogs.
4.3
CONTRAINDICATIONS
Do not use in pregnant or lactating animals.
Do not use in animals suffering from gastrointestinal disorders such
as irritation and haemorrhage,
impaired hepatic, cardiac or renal function and haemorrhagic
disorders.
Do not use in case of hypersensitivity to the active substance or to
any of the excipients.
Do not use in dogs less than 6 weeks of age.
This product is for dogs and should not be used in cats as it is not
suitable for use in this species.
4.4
SPECIAL WARNINGS FOR EACH TARGET SPECIES
None.
4.5
SPECIAL PRECAUTIONS FOR USE
Special precautions for use in animals
If adverse reactions occur, treatment should be discontinued and the
advice of the veterinarian should
be sought.
Avoid use in any dehydrated, hypovolaemic or hypotensive animal, as
there is a potential risk of
increased renal toxicity.
Medicinal product no longer authorised
3
Special precautions to be taken by the person administering the
veterinary medicinal product to
animals
Wash hands after administration of the product.
People with known hypersensitivity to Non Steriodal Anti-inflammatory
Drugs (NSAIDs) should
avoid contact with the veterinary medicinal product.
Avoid direct contact between the product and skin, if accidental
exposure occurs wash hands
immediately with soap and water.
4.6
ADVERSE REACTIONS (FREQUENCY AND SERIOUSNESS)
Typical adverse drug reactions of NSAI
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                Medicinal product no longer authorised
1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
Medicinal product no longer authorised
2
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
RevitaCAM 5 mg/ml oromucosal spray for Dogs
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each ml contains:
ACTIVE SUBSTANCE: Meloxicam 5 mg
EXCIPIENTS: Ethyl alcohol 150 mg
For a full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Oromucosal spray
Yellow colloidal dispersion
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Dogs
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
Alleviation of inflammation and pain in both acute and chronic
musculo-skeletal disorders in dogs.
4.3
CONTRAINDICATIONS
Do not use in pregnant or lactating animals.
Do not use in animals suffering from gastrointestinal disorders such
as irritation and haemorrhage,
impaired hepatic, cardiac or renal function and haemorrhagic
disorders.
Do not use in case of hypersensitivity to the active substance or to
any of the excipients.
Do not use in dogs less than 6 weeks of age.
This product is for dogs and should not be used in cats as it is not
suitable for use in this species.
4.4
SPECIAL WARNINGS FOR EACH TARGET SPECIES
None.
4.5
SPECIAL PRECAUTIONS FOR USE
Special precautions for use in animals
If adverse reactions occur, treatment should be discontinued and the
advice of the veterinarian should
be sought.
Avoid use in any dehydrated, hypovolaemic or hypotensive animal, as
there is a potential risk of
increased renal toxicity.
Medicinal product no longer authorised
3
Special precautions to be taken by the person administering the
veterinary medicinal product to
animals
Wash hands after administration of the product.
People with known hypersensitivity to Non Steriodal Anti-inflammatory
Drugs (NSAIDs) should
avoid contact with the veterinary medicinal product.
Avoid direct contact between the product and skin, if accidental
exposure occurs wash hands
immediately with soap and water.
4.6
ADVERSE REACTIONS (FREQUENCY AND SERIOUSNESS)
Typical adverse drug reactions of NSAI
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 30-05-2016
Summary of Product characteristics Summary of Product characteristics Bulgarian 30-05-2016
Public Assessment Report Public Assessment Report Bulgarian 30-05-2016
Patient Information leaflet Patient Information leaflet Spanish 30-05-2016
Public Assessment Report Public Assessment Report Spanish 30-05-2016
Patient Information leaflet Patient Information leaflet Czech 30-05-2016
Public Assessment Report Public Assessment Report Czech 30-05-2016
Patient Information leaflet Patient Information leaflet Danish 30-05-2016
Public Assessment Report Public Assessment Report Danish 30-05-2016
Patient Information leaflet Patient Information leaflet German 30-05-2016
Public Assessment Report Public Assessment Report German 30-05-2016
Patient Information leaflet Patient Information leaflet Estonian 30-05-2016
Public Assessment Report Public Assessment Report Estonian 30-05-2016
Patient Information leaflet Patient Information leaflet Greek 30-05-2016
Public Assessment Report Public Assessment Report Greek 30-05-2016
Patient Information leaflet Patient Information leaflet French 30-05-2016
Public Assessment Report Public Assessment Report French 30-05-2016
Patient Information leaflet Patient Information leaflet Italian 30-05-2016
Public Assessment Report Public Assessment Report Italian 30-05-2016
Patient Information leaflet Patient Information leaflet Latvian 30-05-2016
Public Assessment Report Public Assessment Report Latvian 30-05-2016
Patient Information leaflet Patient Information leaflet Lithuanian 30-05-2016
Summary of Product characteristics Summary of Product characteristics Lithuanian 30-05-2016
Public Assessment Report Public Assessment Report Lithuanian 30-05-2016
Patient Information leaflet Patient Information leaflet Hungarian 30-05-2016
Summary of Product characteristics Summary of Product characteristics Hungarian 30-05-2016
Public Assessment Report Public Assessment Report Hungarian 30-05-2016
Patient Information leaflet Patient Information leaflet Maltese 30-05-2016
Public Assessment Report Public Assessment Report Maltese 30-05-2016
Patient Information leaflet Patient Information leaflet Dutch 30-05-2016
Public Assessment Report Public Assessment Report Dutch 30-05-2016
Patient Information leaflet Patient Information leaflet Polish 30-05-2016
Public Assessment Report Public Assessment Report Polish 30-05-2016
Patient Information leaflet Patient Information leaflet Portuguese 30-05-2016
Summary of Product characteristics Summary of Product characteristics Portuguese 30-05-2016
Public Assessment Report Public Assessment Report Portuguese 30-05-2016
Patient Information leaflet Patient Information leaflet Romanian 30-05-2016
Public Assessment Report Public Assessment Report Romanian 30-05-2016
Patient Information leaflet Patient Information leaflet Slovak 30-05-2016
Public Assessment Report Public Assessment Report Slovak 30-05-2016
Patient Information leaflet Patient Information leaflet Slovenian 30-05-2016
Summary of Product characteristics Summary of Product characteristics Slovenian 30-05-2016
Public Assessment Report Public Assessment Report Slovenian 30-05-2016
Patient Information leaflet Patient Information leaflet Finnish 30-05-2016
Public Assessment Report Public Assessment Report Finnish 30-05-2016
Patient Information leaflet Patient Information leaflet Swedish 30-05-2016
Public Assessment Report Public Assessment Report Swedish 30-05-2016
Patient Information leaflet Patient Information leaflet Norwegian 30-05-2016
Summary of Product characteristics Summary of Product characteristics Norwegian 30-05-2016
Patient Information leaflet Patient Information leaflet Icelandic 30-05-2016
Summary of Product characteristics Summary of Product characteristics Icelandic 30-05-2016
Patient Information leaflet Patient Information leaflet Croatian 30-05-2016

Search alerts related to this product

View documents history